NCT00837707

Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia

Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan · Other Government
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia

Detailed description

Objective:A few case reports on the use of aripiprazole in neuroleptic-induced tardive dyskinesia have demonstrated positive effects. However its effectiveness in treatment of TD was still inconclusive. The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia. Method: Subjects with pre-existing neuroleptic-induced tardive dyskinesia were chosen from Taoyuan psychiatric center. Patients recruited would be treated with aripiprazole for cross-titration with previous antipsychotics in 8 weeks. We use AIMS, SAS, \& BAS to assess the severity of TF and EPS. We record subjects' age, sex, and other factors which have influence at the treatment response. Subjects are assessed every two weeks in the first month and then monthly until six months.

Conditions

• Dyskinesia, Drug-Induced

Interventions

Type	Name	Description
DRUG	aripiprazole	Flexible dose: 5-30 mg/day

Timeline

• Start date: 2008-06-01
• Primary completion: 2009-08-01
• Completion: 2010-02-01
• First posted: 2009-02-05
• Last updated: 2009-02-05

Locations

1 site across 1 country: Taiwan